Efficacy of Mazdutide in Nondiabetic Adults with Overweight or Obesity: A Meta-Analysis
Mazdutide shows promise in reducing weight and improving cardiometabolic health in nondiabetic adults with obesity, but further research is needed to confirm these results.
Where it sits
this study against the rest of the mazdutide (ibi362) corpusSummary and findings
This meta-analysis assessed the efficacy of mazdutide, a dual GLP-1 and glucagon receptor agonist, in nondiabetic adults with overweight or obesity. The analysis included four RCTs with 918 participants, showing significant reductions in body weight, BMI, and waist circumference. Mazdutide also improved cardiometabolic parameters such as HbA1c, LDL-C, total cholesterol, and triglycerides.
Abstract
<title>Abstract</title> <p>Purpose Mazdutide is a dual GLP-1 and glucagon receptor agonist under investigation for weight management in obesity. This meta-analysis evaluated its efficacy in nondiabetic adults with overweight or obesity. Methods We searched PubMed, Scopus, and Web of Science for randomized controlled trials (RCTs) comparing mazdutide with placebo. Primary outcomes included changes in body weight, BMI, and waist circumference. A random-effects model was used. Results Four RCTs (n = 918) were included. Mazdutide significantly reduced body weight (MD: − 7.72 kg), BMI (–2.84), waist circumference (–5.76 cm), HbA1c (–0.30%), LDL-C (–10.59 mg/dL), total cholesterol (–18.61 mg/dL), and triglycerides (–49.87 mg/dL). Conclusion Mazdutide demonstrates significant improvements in anthropometric and cardiometabolic outcomes in nondiabetic adults with overweight or obesity, supporting its role as a promising option in overweight and obesity pharmacotherapy.</p>
Background
Mazdutide is being investigated as a treatment option for weight management in individuals with obesity, given its dual action on GLP-1 and glucagon receptors. The need for effective pharmacotherapy in obesity is critical due to the associated health risks. This study aims to synthesize existing RCT data to evaluate the efficacy of mazdutide in this population.
Methods
The meta-analysis included RCTs sourced from PubMed, Scopus, and Web of Science. The studies compared mazdutide with placebo in nondiabetic adults with overweight or obesity. Primary outcomes were changes in body weight, BMI, and waist circumference, analyzed using a random-effects model.
Results
Mazdutide significantly reduced body weight by –7.72 kg, BMI by –2.84, and waist circumference by –5.76 cm. Additionally, it improved cardiometabolic markers, including a reduction in HbA1c by –0.30%, LDL-C by –10.59 mg/dL, and triglycerides by –49.87 mg/dL.
Interpretation
The findings suggest that mazdutide has a significant impact on both anthropometric and cardiometabolic outcomes in nondiabetic adults with overweight or obesity. While the effect sizes are statistically significant, the clinical significance should be interpreted cautiously due to the limited number of studies and participants. Further research is needed to confirm these findings and assess long-term effects.
Key findings
- Body weight reduced by –7.72 kg.
- BMI decreased by –2.84.
- Waist circumference reduced by –5.76 cm.
- HbA1c decreased by –0.30%.
- LDL-C reduced by –10.59 mg/dL.
- Triglycerides decreased by –49.87 mg/dL.
Limitations
- Small number of RCTs (n=4).
- Total sample size of 918.
- Short-term outcomes only.
- Potential publication bias in meta-analysis.